Last quarter, Goldman Sachs BDC gave investors a cleaner balance sheet and better credit numbers, but it also gave them a puzzle. Net investment income jumped to $0.38 a share from $0.22, yet roughly $5 million of that came from accelerated discount accretion and a restored accrual that management does not expect to repeat. Strip those out and the run rate looks closer to the low-to-mid $0.30s, uncomfortably near the $0.32 base dividend that management reaffirmed. When the lender reports after the close on November 5, the central question is whether recurring earnings can fill the hole left by those one-off items.
The Street is betting they largely can. Consensus calls for EPS of $0.37 on revenue of $86.2 million, which would match last quarter's adjusted figure and nudge total investment income above the $83.7 million just reported. Compared with a year ago, that still represents contraction, with EPS expected to fall 7.5% and revenue 5.9%. The more telling comparison is sequential. Holding earnings flat while one-time income rolls off would imply either meaningful fee and prepayment income, perhaps from the expected final Thrasio repayment, or a portfolio that is earning more than its recent trajectory suggests. That is a fairly demanding bar.
The reason it is demanding lies in deployment. New commitments shrank to about $12.9 million across nine companies last quarter, down from $46.5 million in the prior quarter and more than $390 million in each of the two quarters before that. Portfolio yield slipped to 9.5% from 9.9%, and management cut leverage to 1.35x with a pro forma figure below its 1.25x target. A smaller, lower-yielding book is hard to square with rising revenue. Management argued that M&A and deal flow picked up after quarter end and that new loans are pricing at a weighted spread of about 511 basis points with conservative loan-to-value ratios. The large Burgess Pigment financing in June should also contribute a full quarter of income. Commitments rebounding toward the $100 million range or higher, at spreads holding near those levels, would validate the recovery story. Another quarter of token originations would challenge it and put dividend coverage squarely in focus.
Credit is the second test. Non-accruals improved to 2.9% of fair value from 3.2%, interest coverage edged up to 2.0x, and workouts at Thrasio and Seneca showed the firm can recover capital. Offsetting that, borrower leverage rose to 6.2x and software lending remains frozen amid worries about AI disruption. Net asset value has drifted down for several quarters, reaching $12.06 from $12.75 a year earlier. Stabilization in NAV would carry as much weight as the earnings line, and with the shares at $8.77, roughly 27% below book, any repurchases under the reactivated $75 million buyback should be accretive. How aggressively management used it will signal its own conviction.
Sentiment has warmed noticeably, moving to a modestly bullish reading from slightly bearish heading into the last report, but the stock has not followed. Shares are down 2.6% since the prior release, lagging the S&P 500 by 2.4 points, and sit below the 200-day moving average of $9.27, closer to the $8.46 low of the post-earnings range than the $10.38 high. The market, in other words, remains skeptical even as the conversation turns more hopeful. The pending handoff to Vivek Bantwal as sole CEO at year end adds a layer of uncertainty about strategy continuity.
Ultimately, this report hinges on whether core income, excluding one-time gains, comfortably covers the $0.32 dividend. If recovering deal flow, wider spreads and stable credit produce that result alongside a steadier NAV, last quarter's cautious optimism holds. If earnings lean again on nonrecurring items while originations stay thin, the discount to book may have further room to persist.